NanoViricides' Lead Drug NV-387 Clears Phase I, Eyes Broad-Spectrum Antiviral Market

TL;DR

**NNVC's NV-387, a broad-spectrum antiviral, just cleared Phase I safety with zero adverse events, making it a high-risk, high-reward bet on a potential paradigm shift in viral treatment.**

AI Summary

NanoViricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company that reported no revenues or profitable operations for the fiscal year ended June 30, 2025. The company successfully completed a Phase Ia/Ib human clinical safety and tolerability trial for its lead drug candidate, NV-387, which is now Phase II-ready. This trial, involving NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, showed no drop-outs or adverse events, indicating high safety and tolerability. NV-387 is a broad-spectrum antiviral designed to target over 90% of human pathogenic viruses by mimicking sulfated proteoglycans. Additionally, NNVC is developing NV-HHV-1 for herpesviruses, which has completed non-clinical studies for a U.S. FDA IND submission, and NV-HIV-1 for HIV, showing effectiveness in animal models. The company maintains fully integrated development and manufacturing facilities in Shelton, CT, enabling rapid drug development.

Why It Matters

NanoViricides' progress with NV-387, a broad-spectrum antiviral, could be a game-changer for investors, employees, and patients, potentially revolutionizing viral infection treatment akin to penicillin's impact on bacterial infections. Its unique mechanism, designed to prevent viral escape, addresses a critical limitation of current antivirals, vaccines, and antibodies, which are often rendered ineffective by viral mutations. This could give NNVC a significant competitive edge against established pharmaceutical companies like Gilead Sciences (GILD) and Merck (MRK) that develop traditional antivirals, especially if NV-387 proves effective across multiple virus families in later clinical stages. Success would mean a substantial market opportunity and a new paradigm for antiviral drug development.

Risk Assessment

Risk Level: high — The company explicitly states, "We have no customers, products or revenues to date, and may never achieve revenues or profitable operations." This indicates significant financial risk. While NV-387 has completed Phase Ia/Ib, it is still in early clinical stages, and the path to commercialization is long, expensive, and uncertain, with no guarantee of FDA approval or market acceptance.

Analyst Insight

Investors should approach NNVC with extreme caution, recognizing it as a highly speculative investment in a clinical-stage biotech with no current revenue. While the Phase Ia/Ib results for NV-387 are promising for safety, further due diligence on upcoming Phase II efficacy trials and the company's financial runway is crucial before considering any position.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (The company has no revenues to date, indicating a pre-commercial stage.)
• 17,431,000 — Shares Outstanding (Approximate common stock shares issued and outstanding on September 27, 2025.)
• $21,530,000 — Market Value of Non-Affiliate Voting Stock (Calculated on December 31, 2024, based on a $1.43 closing price per share.)
• 1 — Phase Ia/Ib Clinical Trial Drop-outs (Zero drop-outs in the NV-387 safety and tolerability trial, indicating good patient retention.)
• 0 — Reported Adverse Events (Zero adverse events reported for NV-387 in Phase Ia/Ib, highlighting its safety profile.)
• 90% — Viruses Targeted by NV-387 (Over 90% of human pathogenic viruses use sulfated proteoglycans, which NV-387 mimics.)
• 1 — Year for COVID Drug Development (Time taken to develop NV-CoV-2 COVID drug from concept to completion of safety/pharmacology studies.)

Key Players & Entities

• NANOVIRICIDES, INC. (company) — Issuer of the 10-K filing
• NV-387 (company) — Lead drug candidate, Phase II-ready
• NV-CoV-2 Oral Syrup (company) — Drug product formulation containing NV-387
• NV-CoV-2 Oral Gummies (company) — Drug product formulation containing NV-387
• NV-HHV-1 (company) — Drug candidate for herpesviruses
• NV-HIV-1 (company) — Drug candidate for HIV
• U.S. Food and Drug Administration (regulator) — Regulatory body for drug approval
• NYSE American (regulator) — Stock exchange where NNVC common stock trades
• Karveer Meditech Pvt. Ltd. (company) — Collaborator for clinical trials
• $21,530,000 (dollar_amount) — Aggregate market value of voting stock held by non-affiliates on December 31, 2024

FAQ

Risk Factors

• No Revenue and Potential for No Profitability [high — financial]: The company has no customers, products, or revenues to date and may never achieve revenues or profitable operations. This pre-commercial stage presents a significant financial risk for investors.
• Clinical Trial Risks [high — regulatory]: The company is developing drug candidates that require extensive clinical trials. There is a risk that future trials may not demonstrate safety or efficacy, leading to delays or discontinuation of development programs.
• Dependence on Key Personnel and Technology [medium — operational]: The success of the company is heavily reliant on its nanoviricides platform technology and the expertise of its key personnel. Any disruption in these areas could significantly impact development timelines and success.
• Competition and Market Acceptance [medium — market]: The biopharmaceutical market is highly competitive. New drugs, including those developed by NanoViricides, face challenges in gaining market acceptance and competing with established treatments.
• Need for Future Funding [high — financial]: As a clinical-stage company with no current revenue, NanoViricides will likely require significant future funding to advance its drug candidates through clinical trials and towards commercialization. Failure to secure such funding could jeopardize its operations.

Industry Context

The biopharmaceutical industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like NanoViricides operate in a highly competitive landscape focused on unmet medical needs, particularly in antiviral therapies where viral resistance is a growing concern. The trend is towards targeted therapies and novel drug delivery mechanisms, such as nanomedicine, to overcome limitations of existing treatments.

Regulatory Implications

As a clinical-stage biopharmaceutical company, NanoViricides faces stringent regulatory oversight from bodies like the U.S. FDA. Successful progression through clinical trials (Phase I, II, III) is mandatory for drug approval. Any delays, adverse findings, or failure to meet regulatory standards can significantly impact development timelines and the ultimate commercial viability of their drug candidates.

What Investors Should Do

1. Monitor clinical trial progress and results
2. Assess future funding requirements and sources
3. Evaluate the competitive landscape for antiviral therapies
4. Review management's strategy for commercialization

Key Dates

• 2005-04-01: Company Incorporated — Marks the initial establishment of NanoViricides, Inc.
• 2023-05-30: Redomiciled to Delaware — Indicates a change in the company's legal domicile, potentially for strategic or financial reasons.
• 2013-09-25: Common Stock Began Trading on NYSE American — Represents a significant milestone for liquidity and investor access, trading under the symbol 'NNVC'.
• 2025-06-30: Fiscal Year End — The period covered by the reported financial data, showing no revenues.
• 2025-09-27: Shares Outstanding Reported — Provides a snapshot of the company's equity structure as of a recent date.
• 2024-12-31: Market Value of Non-Affiliate Voting Stock Calculated — Indicates the market's valuation of the company's publicly traded shares at a specific point.

Glossary

nanoviricides

A class of drugs developed by NanoViricides using nanomedicine technologies to target and dismantle virus particles. (This is the core technology platform of the company, central to all its drug development efforts.)

host-mimetic

A drug designed to mimic features of the host cell that a virus interacts with, making it difficult for the virus to escape through mutation. (Explains a key mechanism of action for nanoviricides, addressing viral evolution challenges.)

direct-acting antiviral

An antiviral drug that directly targets the virus itself, rather than interfering with the host's cellular processes. (Highlights the expected safety and tolerability benefits of nanoviricides compared to traditional antivirals.)

IND-filing stage

The stage in drug development where a company prepares and submits an Investigational New Drug (IND) application to regulatory authorities (like the FDA) to begin human clinical trials. (Indicates that some drug candidates are nearing or ready for human testing, a critical step in the development pipeline.)

Phase Ia/Ib human clinical safety and tolerability trial

Early-stage clinical trials designed to assess the safety, dosage, and side effects of a new drug in a small group of human volunteers. (The successful completion of this trial for NV-387 is a key achievement, demonstrating the drug's safety profile.)

sulfated proteoglycans

Complex molecules found on the surface of host cells that many viruses use to attach and enter cells. (NV-387 mimics these molecules, providing a broad-spectrum mechanism of action against over 90% of human pathogenic viruses.)

Year-Over-Year Comparison

The company continues to operate in a pre-revenue, clinical-stage environment, with no significant changes in its revenue status compared to the previous fiscal year. The primary focus remains on advancing its nanoviricides platform, with NV-387 successfully completing Phase Ia/Ib trials and preparing for Phase II. Development of other candidates like NV-HHV-1 and NV-HIV-1 is progressing through pre-clinical stages. No new material risks appear to have emerged, but the inherent risks of clinical development and the need for future funding persist.

Key Financial Figures

• $0.00001 — g) OF THE ACT: COMMON STOCK, PAR VALUE $0.00001 PER SHARE NYSE AMERICAN (Title of C
• $1.43 — 1,530,000 based on the closing price of $1.43 per share, as reported on the NYSE Amer

Filing Documents

• nnvc-20250630x10k.htm (10-K) — 2187KB
• nnvc-20250630xex23.htm (EX-23) — 4KB
• nnvc-20250630xex31d1.htm (EX-31.1) — 13KB
• nnvc-20250630xex31d2.htm (EX-31.2) — 13KB
• nnvc-20250630xex32d1.htm (EX-32.1) — 7KB
• nnvc-20250630xex32d2.htm (EX-32.2) — 7KB
• 0001104659-25-094527.txt ( ) — 7168KB
• nnvc-20250630.xsd (EX-101.SCH) — 49KB
• nnvc-20250630_cal.xml (EX-101.CAL) — 41KB
• nnvc-20250630_def.xml (EX-101.DEF) — 224KB
• nnvc-20250630_lab.xml (EX-101.LAB) — 389KB
• nnvc-20250630_pre.xml (EX-101.PRE) — 313KB
• nnvc-20250630x10k_htm.xml (XML) — 898KB

Business

Business 3 Item 1A .

Risk Factors

Risk Factors 61 Item 1B . Unresolved Staff Comments 82 Item 1C. Cybersecurity 82 Item 2.

Properties

Properties 83 Item 3.

Legal Proceedings

Legal Proceedings 83 Item 4. Mine Safety Disclosures 83 PART II Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 84 Item 6.

Selected Financial Data

Selected Financial Data 84 Item 7.

Management's Discussion and Analysis of Plan of Operation and Results of Operations

Management's Discussion and Analysis of Plan of Operation and Results of Operations 85 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 91 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 91 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 92 Item 9A.

Controls and Procedures

Controls and Procedures 92 Item 9B. Other Information 92 PART III Item 10. Directors, Executive Officers, Promoters and Corporate Governance. 94 Item 11.

Executive Compensation

Executive Compensation 97 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 98 Item 13. Certain Relationships and Related Transactions and Director Independence 100 Item 14. Principal Accountant Fees and Services 104 PART IV Item 15. Exhibits, Financial Statement Schedules 105 Item 16. Form 10-K Summary 106

SIGNATURES

SIGNATURES 107 Page 1 of 107 Table of Contents PART I SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact made in this report are forward looking. In particular, the statements herein regarding industry prospects and future results of operations or financial position are forward-looking statements. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe," "Company believes," "management believes" and similar language. These forward-looking statements can be identified by the use of words such as "believes," "estimates," "could," "possibly," "probably," "anticipates," "projects," "expects," "may," "will," or "should," or other variations or similar words. No assurances can be given that the future results anticipated by the forward-looking statements will be achieved. Forward-looking statements reflect management's current expectations and are inherently uncertain. The forward-looking statements are based on the current expectations of NanoViricides, Inc. and are inherently subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this report. Our actual results may differ materially from results anticipated in these forward-looking statements. Investors are also advised to refer to the information in our previous filings with the Securities and Exchange Commission (SEC), especially on Forms 10-K, 10-Q and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic results. It is not possible to foresee or identify all such factors. As such, invest

: BUSINESS

ITEM 1: BUSINESS Organization and Nature of Business NanoViricides, Inc. (the "Company", "NanoViricides", "we," or "us") was incorporated in Nevada on April 1, 2005, and redomiciled to Delaware effective May 30, 2023. Our corporate offices are located at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our Website is located at http://www.Nanoviricides.com . We do not incorporate by reference into this Annual Report the information on or accessible through our website, and you should not consider it part of this Annual Report. On September 25, 2013, the Company's common stock began trading on the New York Stock Exchange American under the symbol, "NNVC". We are a clinical stage company with our first drug ready to enter Phase II human clinical efficacy trial, having successfully completed Phase Ia/Ib human clinical safety and tolerability trial. Based on our nanoviricides platform technology, we also have several additional drug candidates in various stages of pre-clinical development, including IND-filing stage and late stage IND-enabling non-clinical studies. We have no customers, products or revenues to date, and may never achieve revenues or profitable operations. We are engaged in developing a class of drugs, that we call nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. This approach enables rapid development of effective new drugs against a number of different viruses, that the viruses are highly unlikely to escape even as they evolve rapidly in the field, solving an important problem in attacking viruses. The virus evolution is known to generate viruses that escape the traditional antiviral approaches vaccines, antibodies and small chemical drugs. Page 3 of 107 Table of Contents NanoViricides Technology Platform Target Product Profile in Brief We are a clinical stage company developing (a) host-mimetic, and (b) direct-a

View Full Filing

View this 10-K filing on SEC EDGAR